+39 02 2412 6830
|
|
|
|
The stability of a drug directly affects the dose a patient receives. The dose received depends on the way the compound is metabolised or accumulated in the body. This metabolism is a key determinant of drug bioavailability. A drug that is rapidly metabolised may require multiple daily dosing or continuous infusion to maintain a concentration in the bloodstream or target organ that is sufficient to elicit a therapeutic effect. However, a slowly metabolised drug may remain in the body for long periods, potentially causing toxic build-up.
Hepatocytes contain enzymes for both phase I (oxidation, reduction and/or hydrolysis of test compound) and phase II (conjugation of test compounds or metabolites) metabolism. |
 |
LGC agrees acquisition of microbiology proficiency testing and reference materials business
LGC to acquire Bio Senate
Leggi tutto >>
Outbreak of kidney failure in Wyoming linked to Spice | The Raw Story
(Reuters) Three young people have been hospitalized with kidney failure and a dozen others sickened in Casper, Wyoming, in an outbreak linked to a ...
Leggi tutto >>
